An interventional study of Thulium Fibre Laser and MOSES Holmium Laser in Benign Prostatic Hyperplasia, sponsored by Thunder Bay Regional Health Research Institute. Recruiting at 1 site in Canada. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.
Sponsored by Thunder Bay Regional Health Research Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Prostatic Hyperplasia with a site in Canada — 11 open to participants now, 16 under way, 3 of them phase 3. Prostatic Hyperplasia · Canada.
Among the 53 studies in Prostatic Hyperplasia with a site in Canada, this one is the 26th largest by planned enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2022, is one of 19 with no phase, reaches primary completion later than 6 of the 15 other live ones, and was the 44th registered.
830 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.
Browse Prostatic Hyperplasia studies →11 of the 53 studies in Prostatic Hyperplasia with a site in Canada are open now. Recruiting first, the newest first:
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Men only
Thunder Bay Regional Health Research Institute · Sites in Canada
Ages 50+ · Men only
Société Internationale d'Urologie · Sites in Canada, United States, Chile and 18 more countries
Ages 18+ · Men only
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Men only
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Men only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 15 · Phase 4 5
First in 2001; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 94 across 629 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 108 across the 47 interventional studies, 956 across the 5 observational. Of the 34 that completed or were terminated, 15 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 53 have an industry lead sponsor. The 10 most frequent:
Thunder Bay Regional Health Research Institute is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Thunder Bay Regional Health Research Institute has 4 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
2 of the studies in Prostatic Hyperplasia with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06769997Centre hospitalier de l'Université de Montréal (CHUM)Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia | 2027-01 |
| NCT07552961University of CalgaryFeasibility and Utility of a Prehabilitation Program for Use in Patients With Benign Prostatic Hyperplasia Who Have Elected to Undergo Holmium Laser Enucleation of the Prostate (HoLEP). | 2027-06-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Prostatic Hyperplasia with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Benign prostatic hyperplasia (BPH), the non-cancerous enlargement of the prostate, places pressure on the urethra and causes urination and bladder problems. Transurethral Resection of the Prostate (TURP) remains the gold standard treatment in most centres for BPH. However, morbidity after TURP is high, especially bleeding requiring blood transfusion and late postoperative bleeding.
Holmium laser enucleation of the prostate (HoLEP) is a safe and effective procedure which has demonstrated comparable results to TURP. HOLEP also offers patients the alternative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay. The main reason HoLEP has yet to become the new standard for treatment of symptomatic BPH is due the complexity of this procedure as compared to TURP. Furthermore, the HoLEP can be used with the MOSESTM system, a system that allows for more efficiency and ease of use of the HoLEP.
Thulium fiber laser (TFL) enucleation of the prostate is an emerging technology for endoscopic prostate enucleation that is notable for its high wavelength and pulsed mode of action. Recent studies have shown TFL enucleation of the prostate to be a safe and highly efficacious treatment modality for the management of large volume (> 80 cm3) glands in BPH. Due to its novelty, further studies are needed to broaden the investigators' understanding of the TFL and comprehend the full implications and benefits of this new technology, as well its limitations.
The aim of this study is to whether Thulium Fiber laser enucleation of the prostate (ThuFLEP) and Holmium laser enucleation using MOSES™ (M-HoLEP) have comparable length of hospital stay, as well as intraoperative and postoperative outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to this arm will undergo treatment using the TFL.
Device: Thulium Fibre Laser
Patients randomized to this arm will undergo treatment using the MOSES Holmium laser.
Device: MOSES Holmium Laser
Participants will undergo treatment using the TFL
Participants will undergo treatment using the MOSES Holmium laser.
Length of stay in the hospital
Time frame: within 6 hours
Incidence of bleeding
Time frame: Intra-Op
Incidence of blood transfusion
Time frame: Intra-Op
Operative time
Including laser use time
Time frame: Intra-Op
International Prostate Symptom Score
Eight questions (seven concerning urinary symptoms and one concerning quality of life), responses range from 0 (better outcome) to 5 (worse outcome), with total score ranging from 0 to 35.
Time frame: 1,3,6,12 months post-op
Quality of Life (QOL) as scored on the International Prostate Symptom Score (IPSS)
Response to the last question on the IPSS: "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?" Response ranging from 'Delighted' to 'Terrible'.
Time frame: 1,3,6,12 months post-op
Peak flow rate
Qmax
Time frame: 1,3,6,12 months post-op
Post-void residual
PVR
Time frame: 1,3,6,12 months post-op
Prostate specific antigen
PSA
Time frame: 1,3,6,12 months post-op
Change in size
Assessed by TRUS
Time frame: 6 months
Time to Catheter Removal
Time frame: within 4 hours
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2022 (actual). Primary completion is estimated for Apr 2025, 36 months after the start.
Of 153 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 36 months is above that.
Counting every sponsor, half of 205 studies reached it within 26 months; a quarter within 15 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Thunder Bay Regional Health Research Institute